PCG
ALNY icon

Prosperity Consulting Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Prosperity Consulting Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Buy
1,152
+111
+11% +$33.5K 0.01% 460
2026
Q1 		$344K Hold
1,041
– – 0.02% 399
2025
Q4 		$414K Buy
+1,041
New +$461K 0.02% 388

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosperity Consulting Group's ALNY Position: Q2 2026 in Review

Prosperity Consulting Group increased its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, buying an estimated $33.5K and bringing the position to 1,152 shares worth $347K. The position accounts for 0.01% of the portfolio, ranked #460.

Prosperity Consulting Group first reported a position in ALNY in Q4 2025 and has held it in 3 quarters since. The position peaked at $414K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Prosperity Consulting Group held 1,152 shares of Alnylam Pharmaceuticals worth $347K as of Q2 2026.
  • Prosperity Consulting Group bought 111 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $33.5K.
  • Alnylam Pharmaceuticals made up 0.01% of Prosperity Consulting Group's portfolio in Q2 2026, its #460 holding.
  • Prosperity Consulting Group first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Prosperity Consulting Group's Alnylam Pharmaceuticals position peaked at $414K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Prosperity Consulting Group's 13F filing for Q2 2026, filed 13 Aug 2026.